Modality
siRNA
MOA
EGFRi
Target
C5
Pathway
Neuroinflam
Pancreatic CaMigraine
Development Pipeline
Preclinical
~Dec 2017
→ ~Mar 2019
Phase 1
Jun 2019
→ Jan 2026
Phase 1Current
NCT07180887
1,233 pts·Pancreatic Ca
2019-06→2026-01·Completed
1,233 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-113mo agoPh2 Data· Pancreatic Ca
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1/2
Complet…
Catalysts
Ph2 Data
2026-01-11 · 3mo ago
Pancreatic Ca
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07180887 | Phase 1/2 | Pancreatic Ca | Completed | 1233 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| GIL-8529 | Gilead Sciences | Phase 1/2 | JAK1 | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| Elratapinarof | Halozyme | Phase 2 | C5 |